Epilepsies in children, young people and adults

Supporting evidence

• Evidence review

• Evidence reviews – April 2022

• 1: Prediction of second seizure (PDF 673 KB)

  Published:

  27 April 2022

• 2: Modifiable risk factors for a second seizure (PDF 801 KB)

  Published:

  27 April 2022

• 3: Diagnosis of epilepsies (PDF 3.81 MB)

  Published:

  27 April 2022

• 4: Information and support (PDF 1.48 MB)

  Published:

  27 April 2022

• 5: New technologies (PDF 742 KB)

  Published:

  27 April 2022

• 6: Safety of antiseizure medications in women and girls (PDF 2.44 MB)

  Published:

  27 April 2022

• 7: Monitoring (PDF 996 KB)

  Published:

  27 April 2022

• 8: Therapeutic drug monitoring in women and girls (PDF 1.09 MB)

  Published:

  27 April 2022

• 9: Antiseizure medication for status epilepticus (PDF 2.92 MB)

  Published:

  27 April 2022

• 10: Antiseizure medications for repetitive/cluster seizures: monotherapy and add-on therapies (PDF 968 KB)

  Published:

  27 April 2022

• 11: Antiseizure medication for prolonged seizures: monotherapy (PDF 638 KB)

  Published:

  27 April 2022

• 12: Ketogenic diets for drug-resistant epilepsy (PDF 523 KB)

  Published:

  27 April 2022

• 13: Referral and surgical interventions (PDF 1.29 MB)

  Published:

  27 April 2022

• 14: Vagus nerve stimulation (PDF 837 KB)

  Published:

  27 April 2022

• 15: Prevalence of psychological disorders in people with epilepsies (PDF 821 KB)

  Published:

  27 April 2022

• 16: Psychological treatments for people with epilepsies (PDF 523 KB)

  Published:

  27 April 2022

• 17: Prediction of death, including SUDEP, in people with epilepsy (PDF 666 KB)

  Published:

  27 April 2022

• 18: Modifiable risk factors for epilepsy related mortality (PDF 1.72 MB)

  Published:

  27 April 2022

• 19: Reducing the risk of seizure-related mortality, including SUDEP (PDF 582 KB)

  Published:

  27 April 2022

• 20: Transition from paediatric to adult epilepsy services (PDF 601 KB)

  Published:

  27 April 2022

• A: Magnetic resonance imaging scan to detect relevant abnormalities in people with epilepsy (PDF 2.37 MB)

  Published:

  27 April 2022

• B: Computed tomography scan performance in people with epilepsy (PDF 2.33 MB)

  Published:

  27 April 2022

• C: Effectiveness of genetic testing in determining the aetiology of epilepsy (PDF 1.69 MB)

  Published:

  27 April 2022

• D: Antibody testing in epilepsy (PDF 954 KB)

  Published:

  27 April 2022

• E: Monotherapy for generalised tonic-clonic and focal onset seizures (PDF 362 KB)

  Published:

  27 April 2022

• F: Add-on therapy for generalised tonic-clonic and focal onset seizures (PDF 1.47 MB)

  Published:

  27 April 2022

• G: Effectiveness of antiseizure therapies in the treatment of absence seizures (PDF 1009 KB)

  Published:

  27 April 2022

• H: Effectiveness of antiseizure therapies in the treatment of myoclonic seizures (PDF 964 KB)

  Published:

  27 April 2022

• I: Effectiveness of antiseizure therapies in the treatment of tonic or atonic seizures/drop attacks (PDF 1.13 MB)

  Published:

  27 April 2022

• J: Effectiveness of antiseizure therapies in the treatment of idiopathic generalised epilepsies, including juvenile myoclonic epilepsy (PDF 1.25 MB)

  Published:

  27 April 2022

• K: Effectiveness of antiseizure therapies in the treatment of Dravet syndrome (PDF 854 KB)

  Published:

  27 April 2022

• L: Effectiveness of antiseizure therapies in the treatment of Lennox-Gastaut syndrome (PDF 1.06 MB)

  Published:

  27 April 2022

• M: Discontinuation of pharmacological treatment (PDF 1.43 MB)

  Published:

  27 April 2022

• N: Criteria for referral to specialist services (PDF 470 KB)

  Published:

  27 April 2022

• O: Effectiveness of a nurse specialist in the management of epilepsy (PDF 2.41 MB)

  Published:

  27 April 2022

• P: Effectiveness of antiseizure therapies for infantile spasms (PDF 1.83 MB)

  Published:

  27 April 2022

• Q: Effectiveness of antiseizure medications for self-limited epilepsy with centrotemporal spikes (PDF 1002 KB)

  Published:

  27 April 2022

• R: Effectiveness of antiseizure therapies for epilepsy with myoclonic-atonic seizures (Doose syndrome) (PDF 496 KB)

  Published:

  27 April 2022

• Economic analysis

• Health economics (PDF 354 KB)

  Published:

  27 April 2022

• Cost effectiveness of antiseizure therapies for people with focal and generalised tonic-clonic seizures (PDF 1.12 MB)

  Published:

  27 April 2022

• Cost effectiveness of resective epilepsy surgery in adults (PDF 1.16 MB)

  Published:

  27 April 2022

• Other supporting evidence

• Methods (NGA) (PDF 401 KB)

  Published:

  30 January 2025

• Methods (NGC) (PDF 1.11 MB)

  Published:

  30 January 2025

• Methods (January 2025) (PDF 257 KB)

  Published:

  30 January 2025